INAB fundamentals
Key facts
Market capitalization19.73 MUSD
Basic EPS (TTM)−0.75USD
Founded2016
CEOWilliam T. Ho
Websitein8bio.com
About
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−10.00 M
−7.50 M
−5.00 M
−2.50 M
0.00
Revenue
Net income
Net margin %
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
INAB does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company